FAQs

Research reagents for breast cancer subtypes. Covers HER2, ER/PR, BRCA1/2, Ki-67, TROP2, and PD-L1 with IHC, flow cytometry, and biosimilar reference antibodies.

Research reagents for colorectal cancer. Covers MSI/MMR markers (MLH1, MSH2, MSH6, PMS2), KRAS/BRAF mutations, EGFR targeting, CEA, and immunotherapy in CRC.

Research reagents for melanoma. Covers BRAF V600E, melanocyte lineage markers (SOX10, MITF, S100, Melan-A), immune checkpoint targets, and biosimilar reference antibodies.

Research reagents for lymphoma (NHL, HL) and leukemia (AML, ALL, CLL). Covers diagnostic CD markers, flow cytometry phenotyping panels, and biosimilar reference antibodies.

Research reagents for pancreatic ductal adenocarcinoma (PDAC). Covers KRAS mutations, Claudin 18.2, Mesothelin, CA19-9, and emerging immunotherapy targets.

Research reagents for hepatocellular carcinoma (HCC). Covers AFP, GPC3, PD-L1, VEGFR-2, and combination immunotherapy targets.

Research reagents for glioblastoma (GBM) and brain tumors. Covers EGFR/EGFRvIII, IDH1 R132H, MGMT, GFAP, and emerging immunotherapy approaches for CNS tumors.

Guide to designing IHC panels for cancer diagnosis. Covers marker selection by tumor type (lung, breast, CRC, lymphoma, melanoma), panel logic, and antibody selection for differential diagnosis.

Guide to flow cytometry for tumor-infiltrating lymphocyte (TIL) analysis. Covers panel design for T cell exhaustion, Treg identification, myeloid phenotyping, and functional analysis.

Guide to using research biosimilar antibodies in PK and ADA bioanalytical assay development. Covers assay formats (bridging ELISA, ECL, sandwich), reference standard selection, and regulatory considerations.